(Q37773994)

23 August 2017

1 reference

title

Treatment of thromboembolism in cancer patients (English)

1 reference

23 August 2017

1 reference

Marina Panova-Noeva

1

1 reference

23 August 2017

Anna Falanga

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

published in

1 reference

23 August 2017

volume

11

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

2049-2058

1 reference

Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Cancer and thrombosis: from molecular mechanisms to clinical presentations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Thrombosis and cancer: Trousseau syndrome revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Thromboembolism in hospitalized neutropenic cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Venous thromboembolism in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Arterial and venous thrombotic complications with thalidomide in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Inferior vena cava filter placement in late-stage cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Use of inferior vena caval filters and survival in patients with malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Idraparinux versus standard therapy for venous thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Extended prophylaxis of venous thromboembolism with idraparinux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Procoagulant mechanisms in tumour cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Mechanisms of heparin induced anti-cancer activity in experimental cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Effect of anticoagulant drugs in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

Prognosis of Cancers Associated with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.494181

10.1517/14656566.2010.494181

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference